Actualización en el tratamiento de la coinfección por VIH y VHC en pacientes adultos

Palabras clave: VIH, VHC, Agentes antivirales directos, Hepatocarcinoma, Interferón

Resumen

Resumen: El presente artículo es una revisión sobre el tratamiento del VHC en pacientes infectados por el VIH. Se aborda brevemente el contexto epidemiológico, la interacción existente entre ambos virus, y la historia natural e inmunopatogenia del VHC. Posteriormente se analizan las estrategias históricas (que incluían el interferón pegilado) y las actuales con los nuevos agentes antivirales directos. Se profundiza en las indicaciones, el concepto de respuesta viral sostenida, la eficacia, la toxicidad, y el tratamiento en situaciones especiales como la infección aguda por VHC o el trasplante hepático. Por último, se aborda la evolución de la fibrosis hepática, el trasplante hepático, el riesgo de hepatocarcinoma y el impacto poblacional de la curación de la infección por VHC.

 

Citas

Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet (London, England). 2016;388(10049):1081-1088. doi:10.1016/S0140-6736(16)30579-7.

Internet. UNAIDS. Data 2017. United Nations Program HIV/AIDS.

Berenguer J, Rivero A, Jarrín I, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infect Dis. 2016;3:1-9.

Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;31 Suppl 1:135-139. doi:10.1111/j.1478-3231.2010.02394.x.

Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology. 2015;62(6):1871-1882. doi:10.1002/hep.28150.

Ingiliz P, Rockstroh JK. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Curr Opin HIV AIDS. 2015;10(5):303-308. doi:10.1097/COH.0000000000000187.

Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int. 2007;27(1):40-46. doi:10.1111/j.1478-3231.2006.01344.x.

Echeverria N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7(6):831-845. doi:10.4254/wjh.v7.i6.831.

Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-2438. doi:10.1056/NEJMcp1006613.

Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68. doi:10.1016/j.jhep.2014.07.012.

Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky J-M. Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5-19. doi:10.1002/hep.20032.

Sharma G, Raheja H, Das S. Hepatitis C virus: Enslavement of host factors. IUBMB Life. 2018;70(1):41-49. doi:10.1002/iub.1702.

Dedania B, Wu GY. Dermatologic Extrahepatic Manifestations of Hepatitis C. J Clin Transl Hepatol. 2015;3(2):127-133. doi:10.14218/JCTH.2015.00010.

Nicot F, Alric L, Barange K, et al. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol. 2011;83(3):437-444. doi:10.1002/jmv.21976.

Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. New Microbiol. 2005;28(1):23-29.

Santos Gil I, Sanz Sanz J. [Treatment with interferon and ribavirin of chronic hepatitis C in HIV-infected patients]. An Med Interna. 2004;21(8):369-372.

Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-1546. doi:10.1002/hep.24549.

Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206. doi:10.1056/NEJMoa1010494.

Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416. doi:10.1056/NEJMoa1012912.

De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology. 2012;56(6):2106-2115. doi:10.1002/hep.25962.

Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England). 2010;376(9742):705-716. doi:10.1016/S0140-6736(10)60934-8.

Kondili LA, Romano F, Rolli FR, et al. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017;66(6):1814-1825. doi:10.1002/hep.29399.

Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353-361. doi:10.1001/jama.2014.7734.

Molina J-M, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet (London, England). 2015;385(9973):1098-1106. doi:10.1016/S0140-6736(14)62483-1.

Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-1239. doi:10.1001/jama.2015.1373.

Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol 373. United States; 2015. doi:10.1056/NEJMoa1501315.

Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223-1231. doi:10.1001/jama.2015.1328.

Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol 373. United States; 2015. doi:10.1056/NEJMoa1503153.

Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. lancet HIV. 2015;2(8):e319-27. doi:10.1016/S2352-3018(15)00114-9.

Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet (London, England). 2015;385(9973):1075-1086. doi:10.1016/S0140-6736(14)61795-5.

Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017;65(1):6-12. doi:10.1093/cid/cix260.

Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67(7):1010-1017. doi:10.1093/cid/ciy220.

Back D, Khoo S. HEP Drug Interactions. https://www.hep-druginteractions.org/checker.

EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi:10.1016/j.jhep.2018.03.026.

Schmid P, Bregenzer A, Huber M, et al. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS One. 2015;10(9):e0138838. doi:10.1371/journal.pone.0138838.

Perez-Latorre L, Rivero-Juarez A, Hontanon V, et al. Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C. Open forum Infect Dis. 2016;3(4):ofw212. doi:10.1093/ofid/ofw212.

Merchante N, Tellez F, Rivero-Juarez A, et al. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. BMC Infect Dis. 2015;15:557. doi:10.1186/s12879-015-1291-3.

Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30-36. doi:10.1111/liv.12576.

Juanbeltz R, Perez-Garcia A, Aguinaga A, et al. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One. 2018;13(12):e0208554. doi:10.1371/journal.pone.0208554.

Lombardi A, Mondelli MU. Hepatitis C: Is eradication possible? Liver Int. 2019;39(3):416-426. doi:10.1111/liv.14011.

Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM policy Pract. 2018;3(1):2381468318776634. doi:10.1177/2381468318776634.

Greenaway C, Makarenko I, Chakra CNA, et al. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health. 2018;15(9). doi:10.3390/ijerph15092013.

Publicado
29-11-2019
Sección
Mesa redonda de VIH